About Us

Changing Best Practices for Life-threatening Disease

Acasti is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. 

Our clinical assets have been awarded Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States.  We have additional intellectual property protection with over 40 granted and pending patents.


Our lead drug candidate, GTX-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH). This formulation offers several potential advantages over oral administration of nimodipine that is the current Standard of Care (SoC).

We believe GTX-104 may represent a significant improvement in the treatment and management of aSAH patients.

Discover More About GTX-104

Our Pipeline

Our pipeline targets underserved orphan diseases with sizable market opportunities in aSAH, Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN).

View Our Pipeline

Partnership Opportunities

We're focused on developing therapeutics for rare and orphan diseases by working with a dedicated group of scientists, world-class academic medical centers, and patient advocacy groups. If you are interested in partnering with us, please contact us.

Contact Us for Partnerships

Proven Leadership

We have a foundation of innovative science backed by a proven team of highly experienced industry experts with clinical, regulatory, operational and commercial success.

View Our Management Team